1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 4, 3, 1, 6, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Benign Prostatic Hyperplasia - Overview
- Benign Prostatic Hyperplasia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Benign Prostatic Hyperplasia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
- AiViva BioPharma Inc
- Aphios Corp
- Aquestive Therapeutics Inc
- ASKA Pharmaceutical Holdings Co Ltd
- BCWorld Pharm Co Ltd
- Boryung Pharmaceutical Co Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Curadis GmbH
- DongKoo Bio & Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- GemVax & KAEL Co Ltd
- Genu Pharma Co Ltd
- Geropharm
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Kangyuan Pharmaceutical Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Nymox Pharmaceutical Corp
- Sentan Pharma Inc
- ValiRx Plc
- Veru Inc
- XuanZhu Biological Technology Co Ltd
- Benign Prostatic Hyperplasia - Drug Profiles
- (dutasteride + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- (dutasteride + tamsulosin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- (finasteride + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- (mirabegron + tamsulosin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- AIV-007 - Drug Profile
- Product Description
- Mechanism Of Action
- AKP-009 - Drug Profile
- Product Description
- Mechanism Of Action
- BCWPE-004 - Drug Profile
- Product Description
- Mechanism Of Action
- BR-9006 - Drug Profile
- Product Description
- Mechanism Of Action
- CKD-843 - Drug Profile
- Product Description
- Mechanism Of Action
- CR-1447 - Drug Profile
- Product Description
- Mechanism Of Action
- DDCI-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Benign Prostatic Hyperplasia and Overactive Bladder - Drug Profile
- Product Description
- Mechanism Of Action
- fadanafil - Drug Profile
- Product Description
- Mechanism Of Action
- fexapotide triflutate - Drug Profile
- Product Description
- Mechanism Of Action
- GP-20051 - Drug Profile
- Product Description
- Mechanism Of Action
- KD-304 - Drug Profile
- Product Description
- Mechanism Of Action
- KKM-1202 - Drug Profile
- Product Description
- Mechanism Of Action
- Quinolixin - Drug Profile
- Product Description
- Mechanism Of Action
- S-0131632 - Drug Profile
- Product Description
- Mechanism Of Action
- SP-0051 - Drug Profile
- Product Description
- Mechanism Of Action
- Sperol - Drug Profile
- Product Description
- Mechanism Of Action
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- tamsulosin SR - Drug Profile
- Product Description
- Mechanism Of Action
- tertomotide - Drug Profile
- Product Description
- Mechanism Of Action
- VAL-301 - Drug Profile
- Product Description
- Mechanism Of Action
- Benign Prostatic Hyperplasia - Dormant Projects
- Benign Prostatic Hyperplasia - Discontinued Products
- Benign Prostatic Hyperplasia - Product Development Milestones
- Featured News & Press Releases
- Dec 13, 2021: Veru announces FDA approval of ENTADFI, a new treatment for benign prostatic hyperplasia
- Feb 23, 2021: Veru submits new drug application for proprietary TADFIN for BPH
- Jul 10, 2020: Ministry OKs Dongkook's P3 trial into benign prostatic hyperplasia treatment
- Oct 23, 2019: GV1001, shows efficacy as a treatment for Benign Prostatic Hyperplasia
- Jun 26, 2019: Veru announces successful completion of pre-NDA meeting with FDA for tadfin (tadalafil 5mg and finasteride 5mg) combination for the treatment of benign prostatic hyperplasia
- Apr 05, 2019: Gemvax & Kael’s wins nod for P3 trial of benign prostatic hyperplasia treatment
- Jan 31, 2019: ValiRx received Russian Federation & Chinese patent grant allowances for therapeutic compound, VAL301
- Jan 14, 2019: Veru Plans to Submit NDA in 2019
- Dec 03, 2018: Veru announces first patient dosed in bioequivalence clinical trial for combination Tadalafil - Finasteride tablet for benign prostatic hyperplasia
- Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
- Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil
- Jul 26, 2010: Aphios Awarded United States Patent For Compositions And Methods For Inhibiting 5-Alpha Reductase
- Mar 02, 2010: Impax Receives Final FDA Approval For Generic FLOMAX 0.4mg Capsules
- Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX
- Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Benign Prostatic Hyperplasia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Benign Prostatic Hyperplasia - Dormant Projects, 2022
- Benign Prostatic Hyperplasia - Discontinued Products, 2022
- Number of Products under Development for Benign Prostatic Hyperplasia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AiViva BioPharma Inc
- Aphios Corp
- Aquestive Therapeutics Inc
- ASKA Pharmaceutical Holdings Co Ltd
- BCWorld Pharm Co Ltd
- Boryung Pharmaceutical Co Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Curadis GmbH
- DongKoo Bio & Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- GemVax & KAEL Co Ltd
- Genu Pharma Co Ltd
- Geropharm
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Kangyuan Pharmaceutical Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Nymox Pharmaceutical Corp
- Sentan Pharma Inc
- ValiRx Plc
- Veru Inc
- XuanZhu Biological Technology Co Ltd
